Oncology (Cancer) / Hematologic Malignancies Approval Notifications
Oncology (Cancer) / Hematologic Malignancies Approval Notifications
Oncology (Cancer) / Hematologic Malignancies Approval Notifications
The next edition of the AABB Global Transfusion Webcast will stream live on AABB’s LinkedIn page at 10 a.m. ET on Wednesday. Join hosts Quentin…
Siddhartha Mukherjee is something of a biotech Renaissance man. First and foremost, he sees himself as an oncologist. But that core interest has led him…
Potencia tu Marca Personal en Internet con estas herramientas para gestionar tu estrategia de personal branding por tareas.
Are there limits on what people should be allowed to do in the medical or surgical field when they’re not a doctor and not training…
Sam Chang hosts Sophia Kamran to discuss her recent research on bladder cancer. The study, titled “Genomic Tumor Correlates of Clinical Outcomes Following Organ-sparing Chemoradiation…
Key Points. Tumor histology and number of sites of extranodal involvement are prominent risk factors for CNS relapse.The CITI score is a validated risk mod
Diagnostic and therapeutic decision-making in pregnancy with suspected pulmonary embolism (PE) is challenging. European and other international professional societies have proposed various recommendations that are…
Listen to this episode from The Uromigos on Spotify. Nick James discusses this paper, which covers broad issues in prostate cancer – including diagnosis and…
Key Points. Patients with IDH1-R132C have a lower complete remission rate and a trend toward reduced OS.Patients with IDH2-R172K in the European LeukemiaNe
Key Points. Reductions in IDH2 variant allele frequency and molecular clearance with enasidenib were associated with attainment of complete remission.Enasi